MASS Quote, Financials, Valuation and Earnings

InspireMD, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of -503.69%. 908 Devices, Inc.'s return on equity of -41.37% beat InspireMD, Inc.'s return on equity of -121.49%.

908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 52.21%. On the other hand InspireMD, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 139.36%. Given that InspireMD, Inc. has higher upside potential than 908 Devices, Inc., analysts believe InspireMD, Inc. is more attractive than 908 Devices, Inc..

908 Devices, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InspireMD, Inc. has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.446%.

908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InspireMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. InspireMD, Inc. pays out -- of its earnings as a dividend.

908 Devices, Inc. quarterly revenues are $14M, which are larger than InspireMD, Inc. quarterly revenues of $2.5M. 908 Devices, Inc.'s net income of -$14.9M is lower than InspireMD, Inc.'s net income of -$12.7M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while InspireMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 4.05x versus 13.49x for InspireMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of -862.39%. 908 Devices, Inc.'s return on equity of -41.37% beat VolitionRX Ltd.'s return on equity of --.

908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 52.21%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than 908 Devices, Inc., analysts believe VolitionRX Ltd. is more attractive than 908 Devices, Inc..

908 Devices, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

908 Devices, Inc. quarterly revenues are $14M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. 908 Devices, Inc.'s net income of -$14.9M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 4.05x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of -1037.17%. 908 Devices, Inc.'s return on equity of -41.37% beat Catheter Precision, Inc.'s return on equity of -192.05%.

908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 52.21%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1496.69%. Given that Catheter Precision, Inc. has higher upside potential than 908 Devices, Inc., analysts believe Catheter Precision, Inc. is more attractive than 908 Devices, Inc..

908 Devices, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

908 Devices, Inc. quarterly revenues are $14M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. 908 Devices, Inc.'s net income of -$14.9M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 4.05x versus 11.19x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -106.46% compared to 908 Devices, Inc.'s net margin of 3.93%. 908 Devices, Inc.'s return on equity of -41.37% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

908 Devices, Inc. has a consensus price target of $10.00, signalling upside risk potential of 52.21%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than 908 Devices, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than 908 Devices, Inc..

908 Devices, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

908 Devices, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

908 Devices, Inc. quarterly revenues are $14M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. 908 Devices, Inc.'s net income of -$14.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, 908 Devices, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices, Inc. is 4.05x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.